EDGEWISE THERAP. DL-,0001

Servier has completed the acquisition of Edgewise’s muscular dystrophy unit, paying $1.55 billion upfront and up to $1.1 billion in milestones. The deal includes sevasemten, an oral myosin inhibitor in late‑stage development that is being studied in a registration‑relevant cohort study for Becker muscular dystrophy and in phase‑2 studies for Duchenne muscular dystrophy. The transaction is approved by regulators and is intended to strengthen Servier’s pipeline for rare neurological diseases. » Więcej na de.investing.com

Edgewise has completed the sale of sevasemten and its muscular dystrophy business to Servier. The deal includes a $1.55 billion upfront payment plus up to $1.1 billion in milestones; Servier acquires all rights and offered affected employees a transition. Edgewise plans to use the upfront payment to fully fund development of EDG-7500 and will focus going forward on cardiovascular programs with EDG-7500, EDG-15400 and EDG-003. Sevasemten is in late-stage clinical trials for Becker and Duchenne muscular dystrophy and holds orphan-drug and Fast Track status from the FDA; initial readouts from a registrational study are expected in Q4 2026. » Więcej na de.investing.com

Edgewise Therapeutics shares rose to a record high of $43.96 and are currently trading around $44.17, implying a market capitalization of about $4.66 billion. Analysts repeatedly raised price targets (including RBC $59, Truist $52, Leerink $50, Guggenheim $51) following positive Phase‑2/12‑week data for EDG‑7500 and CIRRUS‑HCM. The planned sale of the Duchenne muscular dystrophy unit to Servier for $1.55 billion was also announced. However, InvestingPro data indicate the stock may be overvalued relative to its fair value. » Więcej na de.investing.com

RBC Capital lifted its price target for Edgewise Therapeutics to $59 from $48, citing encouraging 12‑week data from the EDG‑7500 HCM trial that showed favorable safety and efficacy and could allow a Phase 3 design without titration echocardiograms. Earlier this month Edgewise agreed to sell sevasemten and its muscular dystrophy business to Servier for $1.55 billion upfront (up to $2.65 billion total), strengthening its finances. The deal enables Edgewise to refocus as a cardiovascular company advancing EDG‑7500, EDG‑15400 (HFpEF) and EDG‑003. » Więcej na finance.yahoo.com

Edgewise Therapeutics’ stock climbed to a 52-week high of $33.50, 207% above its low of $10.60, with a market capitalization of around $3.56 billion. The 12-month gain is 143.52% and the six-month return is 121%. InvestingPro currently rates the stock as overvalued and notes the company is not yet profitable. Positive study data from the MESA extension on sevasemten and expected 2026 catalysts for EDG‑7500 support analysts’ ratings; several firms have confirmed or raised price targets to about $45–46. » Więcej na de.investing.com